Persistent E-cadherin expression in inflammatory breast cancer

Modern Pathology

Volumn 14, Issue 5, 2001, Pages 458-464

  Kleer, Celina G ^a,c,d   Van Golen, Kenneth L ^b,c   Braun, Thomas ^c   Merajver, Sofia D ^b,c  

^a Department of Pathology ^*  (United States)

^b Division of Hematology Oncology 3216 Cancer Center   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

Breast cancer; E cadherin; Inflammatory breast cancer; Metastasis; Tumor emboli

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CELL ADHESION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR EMBOLISM;

BREAST NEOPLASMS; CADHERINS; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0035031712     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880334     Document Type: Article

References (27)

1. Piera JM, Alonso MC, Ojeda MB, Biete A. Locally advanced breast cancer with inflammatory component: A clinical entity with a poor prognosis. Radiother Oncol 1986;7:199-204.
2. Stocks LH, Patterson FM. Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1976;143:885-9.
3. Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience. J Clin Oncol 1997;15:2873-81.
4. Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast: A report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet 1924;39:580-95.
5. Rosen PP. Rosen's breast pathology. Philadelphia: Lippincott-Raven; 1996.
6. Jaiyesimi I, Buzdar A, Hortobagyi G. Inflammatory breast cancer: A review. J Clin Oncol 1992;10:1014-24.
7. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;51:1451-5.
8. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998;392:190-3.
9. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 1999;24:73-6.
10. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. E-cadherin and a-, β- and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998;3:262-6.
11. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
12. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66:107-19.
13. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1996;105:394-402.
14. Hunt NCA, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch 1997;430:285-9.
15. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999;59:5079-84.
16. Kleer CG, Wojno KJ, Fields K, Singleton TP. Detection of estrogen receptor in carcinomas of the breast using automated immunohistochemistry. Appl Immunohistochem Mol Morphol 1999;7:103-7.
17. Peralta Soler A, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Klein-Szanto AJ, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995; 26:1363-9.
18. Vallorosi CJ, Day KC, Zhao X, Rashid MG, Rubin MA, Johnson KR, et al. Truncation of the β-catenin binding domain of E-cadherin precedes epithelial apoptosis during prostate and mammary involution. J Biol Chem 2000;5:3328-34.
19. Miller JR, Moon RT. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev 1996;10:2527-39.
20. Peifer M. Beta-catenin as oncogene: The smoking gun. Science 1997;275:1752-3.
21. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, et al. E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 1999;274:9656-64.
22. Whitehead I, Kirk H, Kay R. Expression cloning of oncogenes by retroviral transfer of cDNA libraries. Mol Cell Biol 1995; 15:704-10.
23. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 4:2727-32.
24. Moll R, Mitze M, Frizen U, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993;143:1731-42.
25. Rimm D, Sinard J, Morrow J. Reduced alpha-cadherin and E-cadherin expression in breast cancer. Lab Invest 1995;5: 506-12.
26. Berx G, Cleton-Jansen A-M, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14:6107-115.
27. Berx G, Cleton-Jansen A-M, Strumane K, Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996;13:1919-25.